Three patients with gastric cancer who underwent surgery during ramucirumab treatment

Hayato Omori, Sadayuki Kawai, Rie Makuuchi, Tomoyuki Irino, Masanori Tokunaga, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Hirofumi Yasui, Masanori Terashima

Research output: Contribution to journalArticle

Abstract

According to the REGARD and RAINBOW trials, ramucirumab (RAM) was introduced as second-line therapy for advanced or metastatic gastric cancer. RAM may impair wound healing due to the inhibition of angiogenesis; details on the postoperative course of patients who underwent surgery during RAM treatment remain unclear. Between 2011 and 2016, 93 patients with incurable gastric cancer were treated with RAM in our institute. Among them, 3 patients underwent surgery after RAM treatment. Case 1: A 74-year-old man with liver metastasis from gastric cancer was treated with a paclitaxel (PTX) plus RAM regimen. Perforation of the stomach was observed 3 days after final RAM administration. He was successfully treated with omental repair and discharged 19 days after surgery. Case 2: A 31-year-old woman with peritoneal recurrence after total gastrectomy received the PTX plus RAM regimen as second-line treatment. Stenting was performed for rectal stenosis. Perforation of the rectum just proximal of the stent was observed 5 days after final RAM administration. Ileostomy was performed. Closure of the perforation was not obtained until the patient died 210 days after surgery. Case 3: A 60-year-old man with remnant gastric cancer received the PTX plus RAM regimen. Accidentally, the enteral feeding tube was removed. Six weeks after the cessation of RAM administration, the enteral feeding tube was inserted under general anesthesia. He was discharged 4 days after surgery. If surgery is required in patients receiving RAM treatment, sufficient drug withdrawal is desirable. If emergency surgery is needed, less invasive procedures should be selected to the maximum extent possible.

Original languageEnglish
Pages (from-to)1021-1023
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume44
Issue number11
Publication statusPublished - 2017 Nov 1
Externally publishedYes

Fingerprint

Stomach Neoplasms
Therapeutics
Paclitaxel
Ambulatory Surgical Procedures
Enteral Nutrition
ramucirumab
Gastric Stump
Ileostomy
Gastrectomy
Rectum
Wound Healing
General Anesthesia
Stents
Stomach
Pathologic Constriction
Emergencies
Neoplasm Metastasis
Recurrence
Liver

Keywords

  • Gastric cancer
  • Ramucirumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Omori, H., Kawai, S., Makuuchi, R., Irino, T., Tokunaga, M., Tanizawa, Y., ... Terashima, M. (2017). Three patients with gastric cancer who underwent surgery during ramucirumab treatment. Japanese Journal of Cancer and Chemotherapy, 44(11), 1021-1023.

Three patients with gastric cancer who underwent surgery during ramucirumab treatment. / Omori, Hayato; Kawai, Sadayuki; Makuuchi, Rie; Irino, Tomoyuki; Tokunaga, Masanori; Tanizawa, Yutaka; Bando, Etsuro; Kawamura, Taiichi; Yasui, Hirofumi; Terashima, Masanori.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 44, No. 11, 01.11.2017, p. 1021-1023.

Research output: Contribution to journalArticle

Omori, H, Kawai, S, Makuuchi, R, Irino, T, Tokunaga, M, Tanizawa, Y, Bando, E, Kawamura, T, Yasui, H & Terashima, M 2017, 'Three patients with gastric cancer who underwent surgery during ramucirumab treatment', Japanese Journal of Cancer and Chemotherapy, vol. 44, no. 11, pp. 1021-1023.
Omori H, Kawai S, Makuuchi R, Irino T, Tokunaga M, Tanizawa Y et al. Three patients with gastric cancer who underwent surgery during ramucirumab treatment. Japanese Journal of Cancer and Chemotherapy. 2017 Nov 1;44(11):1021-1023.
Omori, Hayato ; Kawai, Sadayuki ; Makuuchi, Rie ; Irino, Tomoyuki ; Tokunaga, Masanori ; Tanizawa, Yutaka ; Bando, Etsuro ; Kawamura, Taiichi ; Yasui, Hirofumi ; Terashima, Masanori. / Three patients with gastric cancer who underwent surgery during ramucirumab treatment. In: Japanese Journal of Cancer and Chemotherapy. 2017 ; Vol. 44, No. 11. pp. 1021-1023.
@article{185c82aca9e24fa0b68fe6c2dd0ff0e9,
title = "Three patients with gastric cancer who underwent surgery during ramucirumab treatment",
abstract = "According to the REGARD and RAINBOW trials, ramucirumab (RAM) was introduced as second-line therapy for advanced or metastatic gastric cancer. RAM may impair wound healing due to the inhibition of angiogenesis; details on the postoperative course of patients who underwent surgery during RAM treatment remain unclear. Between 2011 and 2016, 93 patients with incurable gastric cancer were treated with RAM in our institute. Among them, 3 patients underwent surgery after RAM treatment. Case 1: A 74-year-old man with liver metastasis from gastric cancer was treated with a paclitaxel (PTX) plus RAM regimen. Perforation of the stomach was observed 3 days after final RAM administration. He was successfully treated with omental repair and discharged 19 days after surgery. Case 2: A 31-year-old woman with peritoneal recurrence after total gastrectomy received the PTX plus RAM regimen as second-line treatment. Stenting was performed for rectal stenosis. Perforation of the rectum just proximal of the stent was observed 5 days after final RAM administration. Ileostomy was performed. Closure of the perforation was not obtained until the patient died 210 days after surgery. Case 3: A 60-year-old man with remnant gastric cancer received the PTX plus RAM regimen. Accidentally, the enteral feeding tube was removed. Six weeks after the cessation of RAM administration, the enteral feeding tube was inserted under general anesthesia. He was discharged 4 days after surgery. If surgery is required in patients receiving RAM treatment, sufficient drug withdrawal is desirable. If emergency surgery is needed, less invasive procedures should be selected to the maximum extent possible.",
keywords = "Gastric cancer, Ramucirumab",
author = "Hayato Omori and Sadayuki Kawai and Rie Makuuchi and Tomoyuki Irino and Masanori Tokunaga and Yutaka Tanizawa and Etsuro Bando and Taiichi Kawamura and Hirofumi Yasui and Masanori Terashima",
year = "2017",
month = "11",
day = "1",
language = "English",
volume = "44",
pages = "1021--1023",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "11",

}

TY - JOUR

T1 - Three patients with gastric cancer who underwent surgery during ramucirumab treatment

AU - Omori, Hayato

AU - Kawai, Sadayuki

AU - Makuuchi, Rie

AU - Irino, Tomoyuki

AU - Tokunaga, Masanori

AU - Tanizawa, Yutaka

AU - Bando, Etsuro

AU - Kawamura, Taiichi

AU - Yasui, Hirofumi

AU - Terashima, Masanori

PY - 2017/11/1

Y1 - 2017/11/1

N2 - According to the REGARD and RAINBOW trials, ramucirumab (RAM) was introduced as second-line therapy for advanced or metastatic gastric cancer. RAM may impair wound healing due to the inhibition of angiogenesis; details on the postoperative course of patients who underwent surgery during RAM treatment remain unclear. Between 2011 and 2016, 93 patients with incurable gastric cancer were treated with RAM in our institute. Among them, 3 patients underwent surgery after RAM treatment. Case 1: A 74-year-old man with liver metastasis from gastric cancer was treated with a paclitaxel (PTX) plus RAM regimen. Perforation of the stomach was observed 3 days after final RAM administration. He was successfully treated with omental repair and discharged 19 days after surgery. Case 2: A 31-year-old woman with peritoneal recurrence after total gastrectomy received the PTX plus RAM regimen as second-line treatment. Stenting was performed for rectal stenosis. Perforation of the rectum just proximal of the stent was observed 5 days after final RAM administration. Ileostomy was performed. Closure of the perforation was not obtained until the patient died 210 days after surgery. Case 3: A 60-year-old man with remnant gastric cancer received the PTX plus RAM regimen. Accidentally, the enteral feeding tube was removed. Six weeks after the cessation of RAM administration, the enteral feeding tube was inserted under general anesthesia. He was discharged 4 days after surgery. If surgery is required in patients receiving RAM treatment, sufficient drug withdrawal is desirable. If emergency surgery is needed, less invasive procedures should be selected to the maximum extent possible.

AB - According to the REGARD and RAINBOW trials, ramucirumab (RAM) was introduced as second-line therapy for advanced or metastatic gastric cancer. RAM may impair wound healing due to the inhibition of angiogenesis; details on the postoperative course of patients who underwent surgery during RAM treatment remain unclear. Between 2011 and 2016, 93 patients with incurable gastric cancer were treated with RAM in our institute. Among them, 3 patients underwent surgery after RAM treatment. Case 1: A 74-year-old man with liver metastasis from gastric cancer was treated with a paclitaxel (PTX) plus RAM regimen. Perforation of the stomach was observed 3 days after final RAM administration. He was successfully treated with omental repair and discharged 19 days after surgery. Case 2: A 31-year-old woman with peritoneal recurrence after total gastrectomy received the PTX plus RAM regimen as second-line treatment. Stenting was performed for rectal stenosis. Perforation of the rectum just proximal of the stent was observed 5 days after final RAM administration. Ileostomy was performed. Closure of the perforation was not obtained until the patient died 210 days after surgery. Case 3: A 60-year-old man with remnant gastric cancer received the PTX plus RAM regimen. Accidentally, the enteral feeding tube was removed. Six weeks after the cessation of RAM administration, the enteral feeding tube was inserted under general anesthesia. He was discharged 4 days after surgery. If surgery is required in patients receiving RAM treatment, sufficient drug withdrawal is desirable. If emergency surgery is needed, less invasive procedures should be selected to the maximum extent possible.

KW - Gastric cancer

KW - Ramucirumab

UR - http://www.scopus.com/inward/record.url?scp=85041621836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041621836&partnerID=8YFLogxK

M3 - Article

C2 - 29138380

AN - SCOPUS:85041621836

VL - 44

SP - 1021

EP - 1023

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 11

ER -